Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Mar 19;30(4):1023–1034. doi: 10.1038/s41591-024-02877-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 5 — (a) We observed a trend toward a longer overall survival for patients with undetectable ctDNA throughout the study or patients with undetectable ctDNA post-ICI compared to patients with detectable ctDNA post-ICI induction (median OS not reached for all groups, log-rank p = 0.07). (b) Patients with undetectable ctDNA post-ICI had a trend toward a longer OS compared to patients with detectable ctDNA at post-ICI (median OS not reached for both groups, log-rank p = 0.07). (c) Patients with undetectable ctDNA throughout the study or undetectable ctDNA at the preop timepoint had a longer OS compared to patients with detectable ctDNA (median OS not reached vs not reached vs 23.43 months, respectively, log-rank p = 0.023). (d) When patients with undetectable ctDNA throughout the study were excluded, we observed a trend toward longer OS for patients with undetectable ctDNA preop compared to patients with detectable ctDNA at that time point (median OS not reached vs 23.43 months, respectively, log-rank p = 0.075). (e) Patients with undetectable ctDNA postop had a longer OS compared to patients with detectable ctDNA postop (median OS not reached vs 20.43, respectively, log-rank p = 0.017). (f) In evaluating non-pCR patients, overall survival was not statistically significantly different with respect to post-ICI ctDNA status, likely due to the small number of cases (log-rank p = 0.213).